Pardes Biosciences (Pardes Biosciences) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Pardes Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pardes Biosciences's cash to debt ratio for the quarter that ended in Jun. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pardes Biosciences could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Pardes Biosciences's Cash-to-Debt or its related term are showing as below:

PRDS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 3 years, Pardes Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

PRDS's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.9 vs PRDS: No Debt

Pardes Biosciences Cash-to-Debt Historical Data

The historical data trend for Pardes Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pardes Biosciences Cash-to-Debt Chart

Pardes Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Cash-to-Debt

No Debt

Pardes Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial					No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Pardes Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Pardes Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pardes Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pardes Biosciences's Cash-to-Debt falls into.

Pardes Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pardes Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Pardes Biosciences had no debt ⁽¹⁾.

Pardes Biosciences's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Pardes Biosciences had no debt ⁽¹⁾.

Pardes Biosciences (NAS:PRDS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pardes Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pardes Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pardes Biosciences (Pardes Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pardes Biosciences Inc (NAS:PRDS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2173 Salk Avenue, Suite 250, PMB No. 052, Carlsbad, CA, USA, 92008

Website

https://www.pardesbio.com

Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.

Executives

Fs Development Holdings Ii, Llc	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Opportunity Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Sean P. Brusky	officer: Chief Commercial Officer	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Thomas G Wiggans	director, officer: Chief Executive Officer
Foresite Capital Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Pottage John C Jr	director	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Alsup Laurie Smaldone	director	190 WOOSAMONSA RD, PENNINGTON NJ 08534
Heidi Henson	officer: Chief Financial Officer	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
J Jay Lobell	director	365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Brian Philippe Tinmouth	officer: Chief Business & Strategy Ofcr	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Brian Kearney	officer: Chief Development Officer	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Lee D Arnold	officer: Chief Scientific Officer	C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Uri A Lopatin	director, officer: President and CEO	C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013